Probability of survival from the date of diagnosis compared among CLL subgroups with different CD38 expression levels.

Estimated median survival times for the subgroups with (A) CD38⁺ up to 30% versus greater than 30% were 113 months versus 79 months (P = .13; log-rank test) and for the subgroups with (B) CD38⁺ up to 7% versus more than 7% were 114 months versus 79 months (P_cor = .02; derived from maximally selected log-rank statistics), respectively.